GSK and Irish-Founded Ochre Bio Sign $37.5M Data Licence Agreement to Tackle Liver Disease

Jun 13, 2024, 10:46 AM

GSK has entered into a multi-year data licence agreement with Irish-founded Ochre Bio to further investigate the drivers of liver disease. This partnership marks Ochre Bio's second pharma collaboration for 2024 and involves a $37.5 million deal. The agreement aims to generate new data to deepen the understanding of liver diseases and potentially accelerate the development of innovative therapies. Ochre Bio, an Oxford-based start-up, is expected to leverage this partnership to contribute significantly to the biotech sector's business model evolution.